Table 1. Clinical trials of sapacitabine in solid tumors and hematologic malignancies.

Disease	Stage of clinical trial	Number of Patients	Status	Reference (s)
Advanced solid tumors	Phase I	48	Completed	[15]
Advanced solid tumors	Phase I	40	Completed	[14]
Relapsed acute leukemia & MDS	Phase I	47	Completed	[12],[16]
Advanced solid tumors (in combination with CDK inhibitor seliciclib)	Phase I	NA	Ongoing	[9]
Cutaneous T-cell lymphoma	Phase II	NA	Ongoing	[13]
Elderly AML & MDS	Phase II	NA	Ongoing	[10]
Elderly AML (alternating with decitabine)	Phase I/II	NA	Ongoing	[8]
Elderly AML (SEAMLESS pivotal trial)	Phase III	NA	Ongoing	[7]
CLL (in patients with del11q22-23)	Phase II	NA	Ongoing	[6]
Non-small cell lung cancer	Phase II	NA	Ongoing	[1]

MDS, myelodysplastic syndrome; CDK, Cyclin-dependent kinase; AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; NA, not available.